As the state ages, the prevalence of intelligent dysfunction increases, making it a major community health concern. Biomarkers that can detect intelligent dysfunction early may determine a window for mediations that could delay or block its progress. This review article checks the current state of biomarker research for cognitive dysfunction, containing structural and working neuroimaging, cerebrospinal fluid biomarkers, and blood-located biomarkers. It discusses the strengths and restraints of each type of biomarker and highlights hopeful new areas of research. The item also examines challenges in developing biomarkers for intelligent dysfunction, such as the lack of consent on diagnostic tests and the need for large, lengthwise studies. Overall, the review highlights the potential of biomarkers to upgrade the diagnosis and situation of cognitive dysfunction and the need for resumed research in this area.
Author(s) Details:
Jerin James,
Department of Pharmacology, SRM Medical College Hospital and Research Centre, Kattankulathur, Tamilnadu, India.
Jamuna Rani,
Department of Pharmacology, SRM Medical College Hospital and Research Centre, Kattankulathur, Tamilnadu, India.
V. Sathyanarayanan,
Department of Pharmacology, SRM Medical College Hospital and Research Centre, Kattankulathur, Tamilnadu, India.
Please see the link here: https://stm.bookpi.org/RPST-V9/article/view/10296
Keywords: Alzheimer’s, biomarkers, cognitive dysfunction, neuroimaging